Raha Samraat S. 4

What Happened

• Raha Samraat S., President & CEO and a director of Myriad Genetics, acquired 40,000 shares on March 9, 2026 in an open-market purchase (transaction code P).
• The filing reports a weighted-average price of $5.00 per share for a total reported value of $199,844.

Key Details

• Transaction date: 2026-03-09.
• Price: weighted-average $5.00; footnote states trades occurred at prices ranging from $4.97 to $5.00 inclusive (reporting person will provide breakdown on request).
• Shares acquired: 40,000 (acquired, not sold).
• Shares owned after transaction: not disclosed in this Form 4 filing.
• Filing timeliness: reported with a Form 4 dated the same day (no late filing indicated).
• No 10b5-1 plan, option exercise, gift, or tax-withholding note included in this filing.

Context

• Insider purchases are often watched by investors as a possible positive signal, but the filing does not state the insider’s motive and does not guarantee future performance.
• This was a straight open-market purchase (P); no derivatives or exercises were involved.